AMA Grants Reimbursement Code for PrecisionCHD AI Coronary Heart Disease Test
Wednesday, January 03, 2024
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has achieved a significant milestone as the American Medical Association (AMA) has designated a dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analysis (PLA) code, 0440U, for its AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. PrecisionCHD, developed to assist in CHD diagnosis by analyzing individual genetic and epigenetic biomarkers using artificial intelligence (AI), aims to provide personalized insights for preventing heart attacks and enhancing outcomes.
This innovative test addresses the challenges of limited accessibility, scalability, and cost-effectiveness associated with diagnosing CHD, especially in underserved and minority populations. With its simplicity of requiring only a basic blood draw, the ability to be deployed remotely, and scalability without the need for specialized infrastructure, PrecisionCHD aims to facilitate timely intervention and management.
Cardio Diagnostics underscores its dedication to ensuring broad access to its solutions, viewing the assigned CPT PLA code for PrecisionCHD as a pivotal achievement in its commercialization strategy. The development and validation of PrecisionCHD were detailed in a study recently published in the Journal of the American Heart Association, conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics.
Moreover, PrecisionCHD has gained recognition in the healthcare industry, being included in the Innovative Technology contract bestowed upon Cardio Diagnostics by Vizient, Inc. As the largest provider-driven healthcare performance improvement company in the United States, Vizient's clientele encompasses over 60% of hospitals and 97% of academic medical centers.
This acknowledgment, along with the recent publication and the dedicated CPT PLA code, positions PrecisionCHD as a promising advancement in cardiovascular medicine, offering potential benefits in terms of accessibility, accuracy, and timely intervention for patients at risk of coronary heart disease.